MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

[1]  A. Whittemore,et al.  Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.

[2]  R. Vierkant,et al.  The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins , 2016, Tumor Biology.

[3]  P. Lehenkari,et al.  Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma , 2016, Oncotarget.

[4]  D. Nardo.  Toll-like receptors: Activation, signalling and transcriptional modulation. , 2015 .

[5]  M. Beckmann,et al.  Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study , 2014, British Journal of Cancer.

[6]  W. Chung,et al.  Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[7]  J. George,et al.  Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver , 2014, Clinical Cancer Research.

[8]  J. Cigudosa,et al.  Deletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients , 2014, Molecular oncology.

[9]  F. Benencia,et al.  Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies , 2014, Front. Immunol..

[10]  Cara M Martin,et al.  The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer , 2014, PloS one.

[11]  M. Köbel,et al.  Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry , 2014, Histopathology.

[12]  Guonan Zhang,et al.  Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway , 2014, Scientific Reports.

[13]  C. Mai,et al.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers , 2013, OncoTargets and therapy.

[14]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[15]  Francesmary Modugno,et al.  Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[16]  M. Lux,et al.  Hormone replacement therapy and prognosis in ovarian cancer patients , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  D. Suh,et al.  Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers , 2012, World Journal of Surgical Oncology.

[18]  M. Köbel,et al.  Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma , 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  Stewart G. Martin,et al.  Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival , 2012, Virchows Archiv.

[20]  J. S. Hoffman,et al.  Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers , 2012, Human mutation.

[21]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[22]  Sebastian M. Armasu,et al.  Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  R. Homer,et al.  Airway Epithelial MyD88 Restores Control of Pseudomonas aeruginosa Murine Infection via an IL-1–Dependent Pathway , 2011, The Journal of Immunology.

[24]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[25]  Matthew Burnell,et al.  Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. , 2011, Journal of clinical epidemiology.

[26]  G. Coukos,et al.  Immunotherapy for ovarian cancer: what's next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Reuss,et al.  The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.

[28]  Lian-tang Wang,et al.  Endogenous toll-like receptor ligands and their biological significance , 2010, Journal of cellular and molecular medicine.

[29]  E. Kohn,et al.  Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. , 2010, Cancer research.

[30]  Z. Qian,et al.  High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer , 2010, British Journal of Cancer.

[31]  T. Whiteside,et al.  TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.

[32]  M. Goodman,et al.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. , 2008, Endocrine-related cancer.

[33]  L. Wilkens,et al.  Genetic Polymorphisms in the Paraoxonase 1 Gene and Risk of Ovarian Epithelial Carcinoma , 2008, Cancer Epidemiology Biomarkers & Prevention.

[34]  D. Huntsman,et al.  Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma , 2007, BMC medicine.

[35]  S. Kjaer,et al.  Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[36]  S. Chanock,et al.  Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study , 2007, BMC Cancer.

[37]  A. Whittemore,et al.  Common variants in mismatch repair genes and risk of invasive ovarian cancer. , 2006, Carcinogenesis.

[38]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[39]  R. Ozols.  Systemic therapy for ovarian cancer: current status and new treatments. , 2006, Seminars in oncology.

[40]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[41]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[42]  A. Whittemore,et al.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. , 2004, American journal of epidemiology.

[43]  Shizuo Akira,et al.  Toll-like Receptor Signaling* , 2003, Journal of Biological Chemistry.

[44]  H. Pahl.  Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[45]  ROYAL NORTH SHORE HOSPITAL , 1916 .

[46]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[47]  D. De Nardo,et al.  Toll-like receptors: Activation, signalling and transcriptional modulation. , 2015, Cytokine.

[48]  A. Green,et al.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer , 2008, International journal of cancer.

[49]  樊晓红.  TLR（Toll—like receptor） , 2003 .

[50]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[51]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.